Literature DB >> 15537434

Management of bone loss after organ transplantation.

Adi Cohen1, Philip Sambrook, Elizabeth Shane.   

Abstract

Organ transplant recipients experience rapid bone loss and high fracture rates, particularly during the early post-transplant period. Early rapid bone loss occurs in the setting of uncoupled bone turnover with increased bone resorption and decreased bone formation. Because there are no clinical factors that reliably predict post-transplant bone loss and fractures in the individual patient, all transplant recipients should be considered candidates for early preventive therapy for osteoporosis. Long-term transplant recipients with densitometric osteoporosis and/or fractures should also receive treatment. Although active metabolites of vitamin D and bisphosphonates have both shown efficacy, data from clinical trials suggest that bisphosphonates are the safest and most consistently effective agents for the prevention and treatment of post-transplantation osteoporosis in adults. Kidney transplant recipients represent a special population, and more research is needed to delineate the risks and benefits of treating bone disease in these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537434     DOI: 10.1359/JBMR.040912

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  19 in total

1.  [Sequelae of organ transplantation].

Authors:  S Ciesek; M Manns; C Strassburg
Journal:  Internist (Berl)       Date:  2006-03       Impact factor: 0.743

Review 2.  Metabolic bone diseases in kidney transplant recipients.

Authors:  Rubin Zhang; Kanwaljit K Chouhan
Journal:  World J Nephrol       Date:  2012-10-06

Review 3.  Medication-induced osteoporosis: screening and treatment strategies.

Authors:  Keshav Panday; Amitha Gona; Mary Beth Humphrey
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-10       Impact factor: 5.346

Review 4.  Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.

Authors:  Monica Grover; Laura K Bachrach
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

Review 5.  Mineral and bone disorder after kidney transplantation.

Authors:  Pahnwat T Taweesedt; Sinee Disthabanchong
Journal:  World J Transplant       Date:  2015-12-24

6.  Patients with cirrhosis and ascites have false values of bone density: implications for the diagnosis of osteoporosis.

Authors:  N Guañabens; A Monegal; A Muxi; A Martinez-Ferrer; R Reyes; J Caballería; L Del Río; P Peris; F Pons; A Parés
Journal:  Osteoporos Int       Date:  2011-08-30       Impact factor: 4.507

7.  Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients.

Authors:  Steven W Ing; Loraine T Sinnott; Sirisha Donepudi; Elizabeth A Davies; Ronald P Pelletier; Nancy E Lane
Journal:  Clin Transplant       Date:  2010-10-21       Impact factor: 2.863

8.  Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid.

Authors:  Edmund K Li; Tracy Y Zhu; Vivian Y Hung; Anthony W Kwok; Vivian W Lee; Kenneth K Lee; James F Griffith; Martin Li; Kong Chiu Wong; Ping Chung Leung; Ling Qin; Lai Shan Tam
Journal:  Arthritis Res Ther       Date:  2010-10-22       Impact factor: 5.156

9.  Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats.

Authors:  T Matsunaga; M Shigetomi; T Hashimoto; H Suzuki; T Gondo; H Tanaka; T Sugiyama; T Taguchi
Journal:  Osteoporos Int       Date:  2007-05-10       Impact factor: 4.507

10.  Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption.

Authors:  M Matsubara; E Yamachika; H Tsujigiwa; N Mizukawa; T Ueno; J Murakami; N Ishida; Y Kaneda; N Shirasu; S Takagi
Journal:  Osteoporos Int       Date:  2009-10-08       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.